Vir Biotechnology (VIR) Prepaid Assets (2018 - 2026)
Vir Biotechnology (VIR) posted Prepaid Assets of $44.8 million for Q1 2026, down 0.85% sequentially from $45.1 million in Q4 2025, and up 5.58% YoY from $42.4 million in Q1 2025.
Vir Biotechnology (VIR) Prepaid Assets (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Prepaid Assets for 9 years, with the latest figure at $44.8 million in Q1 2026.
- Quarterly Prepaid Assets rose 5.58% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.8 million (up 5.58% YoY) and the FY2025 annual result came in at $45.1 million, down 5.41% from the prior year.
- Prepaid Assets slipped to $44.8 million in Q1 2026 per VIR's latest filing, from $45.1 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $104.4 million in Q4 2022 and troughed at $4.1 million in Q1 2024.
- A 5-year average of $52.8 million and a median of $45.1 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets plunged 95.8% in 2024, then soared 934.0% in 2025.
- Over 5 years, Prepaid Assets stood at $104.4 million in 2022, then sank by 92.72% to $7.6 million in 2023, then soared by 527.96% to $47.7 million in 2024, then dropped by 5.41% to $45.1 million in 2025, then decreased by 0.85% to $44.8 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $44.8 million, $45.1 million, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.08 Mn |
| Mar 31, 2026 | 44.76 Mn |
| Dec 31, 2025 | 45.14 Mn |
| Sep 30, 2025 | 36.96 Mn |
| Jun 30, 2025 | 41.47 Mn |
| Mar 31, 2025 | 42.39 Mn |
| Dec 31, 2024 | 47.73 Mn |
| Sep 30, 2024 | 43.09 Mn |
| Jun 30, 2024 | 40.73 Mn |
| Mar 31, 2024 | 4.10 Mn |
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 59.43 Mn |
| Jun 30, 2023 | 85.74 Mn |
| Mar 31, 2023 | 97.60 Mn |
| Dec 31, 2022 | 104.36 Mn |
| Sep 30, 2022 | 54.18 Mn |
| Jun 30, 2022 | 72.42 Mn |
| Mar 31, 2022 | 69.91 Mn |
| Dec 31, 2021 | 73.00 Mn |
| Sep 30, 2021 | 27.77 Mn |